Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rintatolimod and IFN Alpha-2b in Cancer Patients with COVID-19
NCT04379518Phase 2Terminated
- Sponsor
- Roswell Park Comprehensive Cancer Center
- Start
- Nov 2020
- Primary completion
- Mar 2023
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), MicroRNA (miRNA)
- Countries
- 1
01
Overview
A Phase 2 trial of rintatolimod in coronavirus disease 2019 (COVID-19), sponsored by Roswell Park Comprehensive Cancer Center. Started Nov 2020; status: terminated.
02
Drugs
rintatolimod
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04379518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04379518.